Publications

The TRIMT co-founder and Managing Partner, Dr. Johannes Notni, has a long-term scientific track record in the fields of coordination chemistry, chelator design, radiopharmaceuticals, radiochemistry and radiotracer production, experimental nuclear medicine, and related areas. Many of the unique molecular structures and technological approaches drive the science and product design of TRIMT GmbH. Papers covering the fundamentals and advances of TRIMT’s technology are highlighted (★).

★ M. C. Kreissl, J. Wuestemann, E. Eppard, D. Hescheler, J. Wybranska, D. Kupitz, F. Reissig, F. G. Almaguel, J. Notni*. First αvβ6-integrin targeted radioligand therapy of breast cancer using Lu-177-Therahexin. Eur. J. Nucl. Med. Mol. Imaging 2026, 53, 4311–4313. DOI: 10.1007/s00259-026-07826-1

★ N. T. Nguyen, T. Rheinfrank, S. Stangl, F. Reissig, S. Kossatz*, J. Notni*. Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer. Mol. Pharmaceut. 2026, DOI: 10.1021/acs.molpharmaceut.6c00256

★ J. Wuestemann, E. Eppard, D. Hescheler, J. Wybranska, D. Kupitz, F. Reissig, F. G. Almaguel, A. Al-Ibraheem, J. Notni*, M. C. Kreissl. Radioligand therapy of pancreatic ductal adenocarcinoma using an αvβ6-integrin targeting ⁶⁸Ga / ¹⁷⁷Lu labeled theranostic pair. Eur. J. Nucl. Med. Mol. Imaging 2026, 53, 4304–4306. DOI: 10.1007/s00259-025-07701-5

★ K. D. Bendová, T. Groll, B. Neužilová, K. Krasulová, Z. Nový, F. Reissig, K. Steiger, M. Boxberg, E. Eppard, J. Wuestemann, M. Hajdúch, M. Jesinghaus, J. Šimeček, M. C. Kreissl*, M. Petřík*, J. Notni*. PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2025, 53, 607–618. 10.1007/s00259-025-07408-7

★ T. Rheinfrank, V. Lebruška, S. Stangl, M. Vojtíčková, N. T. Nguyen, L. Koller, J. Šimeček, V. Kubíček, S. Kossatz*, J. Notni*. Three Is A Magic Number: Tailored Clickable Chelators Used to Determine Optimal RGD-Peptide Multiplicity in αvβ6-Integrin Targeted ¹⁷⁷Lu–labeled Cancer Theranostics. Bioconjugate Chem. 2024, 35, 1970–1984. DOI: 10.1021/acs.bioconjchem.4c00481

★ J. Rehm*, R. Winzer, M. Pretze, J. Müller, J. Notni, S. Hempel, M. Distler, G. Folprecht, J. Kotzerke. αvβ6-Integrin Targeted PET/CT Imaging in Pancreatic Cancer Patients Using ⁶⁸Ga-Trivehexin. Front. Nucl. Med. 2024, 4, 1487602. DOI:10.3389/fnume.2024.1487602

★ J. Rehm*; R. Winzer, J. Notni, S. Hempel, M. Distler, G. Folprecht, J. Kotzerke. Concomitant metastatic head-and-neck cancer and pancreatic cancer assessed by αvβ6-integrin PET/CT using ⁶⁸Ga-Trivehexin: incidental detection of a brain metastasis. Eur. J. Nucl. Med. Mol. Imaging 2024, 51, 3469–3471. DOI:10.1007/s00259-024-06750-6

★ S. Stangl, N. T. Nguyen, J. Brosch-Lenz, J. Šimeček, W. A. Weber, S. Kossatz*, J. Notni*. Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: Considerations on clinical safety profiles. Eur. J. Nucl. Med. Mol. Imaging 2024, 51, 3191–3201. DOI:10.1007/s00259-024-06738-2

★ N. G. Quigley, M. A. Zierke, B. S. Ludwig, F. Richter, N. T. Nguyen, F. Reissig, J. Šimeček, S. Kossatz*, J. Notni*. The importance of tyrosines in multimers of cyclic RGD nonapeptides: towards αvβ6-integrin targeted radiotherapeutics. RSC Med. Chem. 2024, 15, 2018–2029. DOI:10.1039/D4MD00073K

★ N. G. Quigley, K. Steiger, S. F. Färber, F. Richter, W. Weichert, J. Notni*. Sensitive positron emission tomography imaging of PD-L1 expression in human breast and lung carcinoma xenografts using the radiometalated peptide Ga-68-TRAP-WL12. Mol. Pharmaceut. 2024, 21, 1827–1837. DOI:10.1021/acs.molpharmaceut.3c01128

★ N. G. Quigley, F. Richter, S. Kossatz, J. Notni*. Complexity of αvβ6-Integrin Targeting RGD Peptide Trimers: Emergence of Non-Specific Binding by Synergistic Interaction. RSC Med. Chem. 2023, 14, 2564–2573. DOI:10.1039/d3md00365e

J. Notni*. RGD Forever!—Past, Present, and Future of a 3-Letter-Code in Radiopharmacy and Life Sciences. Pharmaceuticals 2023, 16, 56. DOI:10.3390/ph16010056

S. Settelmeier, Z. Varasteh, M. Staniszewska, A.-L. Beerlage, F. Zarrad, W. Fendler, C. Rischpler, J. Notni, M. Totzeck, K. Herrmann, T. Rassaf, U. B. Hendgen-Cotta*. Demonstration of the Early Cardiac Bioavailability of a Non-Specific Cell-Targeted Peptide Using Radionuclide-Based Imaging In Vivo. Pharmaceuticals 2023, 16, 824. DOI:10.3390/ph16060824

★ N. G. Quigley, K. Steiger, S. Hoberück, N. Czech, M. A. Zierke, S. Kossatz, M. Pretze, F. Richter, W. Weichert, C. Pox, J. Kotzerke, J. Notni*. PET/CT imaging of head-and-heck and pancreatic cancer in humans by targeting the „Cancer Integrin“ αvβ6 with Ga-68-Trivehexin. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 1136–1147. DOI:10.1007/s00259-021-05559-x

★ S. Kossatz, A. J. Beer, J. Notni*. It’s time to shift the paradigm: Translation and clinical application of non-αvβ3 integrin targeting radiopharmaceuticals. Cancers 2021, 13, 5958. DOI:10.3390/cancers13235958

★ K. Steiger, N. G. Quigley, T. Groll, F. Richter, M. A. Zierke, A. J. Beer, W. Weichert, M. Schwaiger, S. Kossatz, J. Notni*. There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography. EJNMMI Res. 2021, 11, 106. DOI:10.1186/s13550-021-00842-2

M. A. Kirchner, A. Holzgreve, M. Brendel, M. Orth, V. C. Ruf, K. Steiger, D. Pötter, L. Gold, M. Unterrainer, L. M. Mittlmeier, S. Lindner, L. Kaiser, J. Maas, L. von Baumgarten, H. Ilhan, C. Belka, J. Notni, P. Bartenstein, K. Lauber, N. L. Albert*. PSMA PET imaging in glioblastoma: A preclinical evaluation and theranostic outlook. Front. Oncol. 2021, 11, 774017. DOI:10.3389/fonc.2021.774017

★ N. G. Quigley, N. Czech, W. Sendt, J. Notni*. PET/CT imaging of pancreatic carcinoma targeting the „cancer integrin“ αvβ6. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1407–1408. DOI:10.1007/s00259-021-05443-8

D. Horváth, F. Travagin, N. Guidolin, F. Buonsanti, G. Tircsó, I. Tóth, F. Bruchertseifer, A. Morgenstern, J. Notni, G. B. Giovenzana*, Z. Baranyai*. Towards ²¹³Bi alpha-therapeutics and beyond: unravelling the foundations of efficient Bi^III complexation by DOTP. Inorg. Chem. Front. 2021, 8, 3893–3904. DOI:10.1039/D1QI00559F

S. Gulde, T. Wiedemann, M. Schillmaier, I. Valenca, A. Lupp, K. Steiger, H. Y. Yen, S. Bäuerle, J. Notni, R. Luque, H. Schmid, S. Schulz, D. Ankerst, F. Schilling, N. S. Pellegata*. Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors. Cancers 2021, 13, 3097. DOI:10.3390/cancers13123097

J. Notni*. PSMA-Targeted Therapeutics: A Tale About Law and Economics. J. Nucl. Med. 2021, 62, 1482. DOI:10.2967/jnumed.121.262308

★ N. G. Quigley, K. Steiger, F. Richter, W. Weichert, S. Hoberück, J. Kotzerke, J. Notni*. Tracking a TGF-β Activator In Vivo: Sensitive PET Imaging of αvβ8-Integrin with the Ga-68 Labeled Cyclic RGD Octapeptide Trimer Ga-68-Triveoctin. EJNMMI Res. 2020, 10, 133. DOI:10.1186/s13550-020-00706-1

E. Hacaperková, A. Jaroš, J. Kotek, J. Notni, M. Straka, V. Kubíček*, P. Hermann. Al(III)-NTA-Fluoride: A Simple Model System for Al–F Binding with Interesting Thermodynamics. Dalton Trans. 2020, 49, 13726–13736. DOI:10.1039/d0dt02644a

N. G. Quigley, S. Tomassi, F. S. Di Leva, S. Di Maro, F. Richter, K. Steiger, S. Kossatz, L. Marinelli*, J. Notni*. Click-chemistry (CuAAC) Trimerization of an α_vβ₆-Integrin Targeting Ga-68-Peptide: Enhanced Contrast for In-vivo PET imaging of Human Lung Adenocarcinoma Xenografts. ChemBioChem 2020, 21, 2836–2843. DOI:10.1002/cbic.202000200

F. Bruchertseifer, P. Comba*, B. Martin, A. Morgenstern, J. Notni, M. Starke, H. Wadepohl. First generation bispidine chelators for ²¹³Bi^III radiopharmaceutical applications. ChemMedChem 2020, 15, 1591–1600. DOI:10.1002/cmdc.202000361

J. Notni*, F. T. Gassert, K. Steiger, P. Sommer, W. Weichert, E. J. Rummeny, M. Schwaiger, H. Kessler, R. Meier, M. A. Kimm. In-Vivo Imaging of Early Stages of Rheumatoid Arthritis by α5β1-Integrin Targeted Positron Emission Tomography. EJNMMI Res. 2019, 9, 87. DOI:10.1186/s13550-019-0541-6

E. Farkas, A. Vágner, R. Negri, L. Lattuada, I. Tóth, V. Colombo, D. Esteban-Gómez, C. Platas-Iglesias, J. Notni*, Z. Baranyai*, G. B. Giovenzana*. PIDAZTA: Structurally Constrained Chelators for Efficient Formation of Stable Gallium-68 Complexes at Physiological pH. Chem. Eur. J. 2019, 25, 10698–10709. DOI:10.1002/chem.201901512

F. Reichart, O. V. Maltsev, T. G. Kapp, A. F. B. Räder, M. Weinmüller, U. K. Marelli, J. Notni, A. Wurzer, R. Beck, H.-J. Wester, K. Steiger, S. Di Maro, F. Saverio Di Leva, L. Marinelli, M. Nieberler, U. Reuning, M. Schwaiger, H. Kessler*. Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide. J. Med. Chem. 2019, 62, 2024–2037. DOI:10.1021/acs.jmedchem.8b01588

M. Schottelius,* A. Wurzer, K. Wissmiller, R. Beck, M. Koch, D. Gkorpas, J. Notni, T. Buckle, M. N. van Oosterom, K. Steiger, V. Ntziachristos, M. Schwaiger, F. W. B. van Leeuwen, H.-J. Wester. Synthesis and preclinical characterization of the PSMA-targeted hybrid probe PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. J. Nucl. Med. 2019, 60, 71–78. DOI:10.2967/jnumed.118.212720

A. Wurzer, J. Pollmann, A. Schmidt, D. Reich, H.-J. Wester, J. Notni*. Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results. Mol. Pharmaceutics 2018, 15, 4296–4302. DOI:10.1021/acs.molpharmaceut.8b00602

J. Notni*, H.-J. Wester. ⁶⁸Ga-Radiopharmaka: Methode oder Episode? Der Nuklearmediziner 2018, 41, 335–347.

J. Šimeček, P. Hermann, C. Seidl, F. Bruchertseifer, A. Morgenstern, H.-J. Wester, J. Notni*. Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: Towards improved alpha-therapeutics. EJNMMI Res. 2018, 8, 78. DOI:10.1186/s13550-018-0431-3

S. Procházková, V. Kubíček*, J. Kotek, A. Vágner, J. Notni, P. Hermann. Lanthanide(III) complexes of monophosphinate / monophosphonate DOTA-analogues: effects of the substituents on the formation rate and radiolabelling yield. Dalton Trans. 2018, 13006–13015. DOI:10.1039/c8dt02608d

F. S. Di Leva, S. Tomassi, S. Di Maro, F. Reichart, J. Notni, A. Dangi, U. K. Marelli, D. Brancaccio, F. Merlino, H.-J. Wester, E. Novellino, H. Kessler, L. Marinelli*. From a Helix to a Small Cycle: Metadynamics-Inspired αvβ6 Integrin Selective Ligands. Angewandte Chem. Int. Ed. 2018, 57, 14645–14649; Angewandte Chem. 2018, 130, 14856–14860. DOI:10.1002/anie.201803250

A. Vágner, A. Forgács, E. Brücher, I. Tóth, A. Maiocchi, A. Wurzer, H.-J. Wester, J. Notni, Z. Baranyai*. Equilibrium thermodynamics, formation and dissociation kinetics of trivalent iron and gallium complexes of triazacyclononane-triphosphinate (TRAP) chelators: Unraveling the foundations of highly selective Ga-68 labeling. Front. Chem. 2018, 6, 170. DOI:10.3389/fchem.2018.00170

★ A. Wurzer, A. Vágner, D. Horváth, F. Fellegi, H.-J. Wester, F. K. Kálmán, J. Notni*. Synthesis of symmetrical tetrameric conjugates of the radiolanthanide chelator DOTPI for application in endoradiotherapy by means of click chemistry. Front. Chem. 2018, 6, 107. DOI:10.3389/fchem.2018.00107

T. G. Kapp, F. S. Di Leva, J. Notni, A. F. B. Räder, M. Fottner, D. Reich, A. Wurzer, K. Steiger, E. Novellino, U. K. Marelli, H-J. Wester, L. Marinelli, H. Kessler*. N-methylation of isoDGR Peptides: Discovery of a Selective α5β1-Integrin Antagonist as Potent Tumor Imaging Agent. J. Med. Chem. 2018, 61, 2490–2099. DOI:10.1021/acs.jmedchem.7b01752

S. F. Färber, A. Wurzer, F. Reichart, R. Beck, H. Kessler, H.-J. Wester, J. Notni*. Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6. ACS Omega 2018, 3, 2428–2436. DOI:10.1021/acsomega.8b00035

A. Wurzer, C. Seidl, A. Morgenstern, F. Bruchertseifer, M. Schwaiger, H.-J. Wester, J. Notni*. Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy. Chem. Eur. J. 2018, 24, 547–550. DOI:10.1002/chem.201702335

★ J. Notni*, H.-J. Wester. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals. J. Label. Compd. Radiopharm. 2018, 61, 141–153. DOI:10.1002/jlcr.3582

A. Wacker, F. Carniato, C. Platas-Iglesias, D. Esteban-Gomez, H.-J. Wester, L. Tei*, J. Notni*. Dimer Formation of GdDO3A-Arylsulfonamide Complexes Causes Loss of pH-Dependency of Relaxivity. Dalton Trans. 2017, 46, 16828–16836. DOI:10.1039/c7dt02985c

M. Nieberler*, U. Reuning, F. Reichart, J. Notni, H.-J. Wester, M. Schwaiger, M. Weinmüller, A. Räder, K. Steiger, H. Kessler*. Exploring the Role of RGD-Recognizing Integrins in Cancer. Cancers 2017, 9, 116. DOI:10.3390/cancers9090116

★ K. Steiger, A.-M. Schlitter, W. Weichert, I. Esposito, H.-J. Wester, J. Notni*. Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions. Mol. Imaging 2017, 16, 1536012117709384. DOI:10.1177/1536012117709384

S. Maschauer*, J. Einsiedel, D. Reich, H. Hübner, P. Gmeiner, H.-J. Wester, O. Prante, J. Notni. Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors. Pharmaceuticals 2017, 10, 29. DOI:10.3390/ph10010029

D. Reich, A. Wurzer, M. Wirtz, V. Stiegler, P. Spatz, J. Pollmann, H.-J. Wester, J. Notni*. Dendritic poly-chelator frameworks for multimeric bioconjugation. Chem. Commun. 2017, 53, 2586–2589. DOI:10.1039/c6cc10169k

★ J. Notni*, D. Reich, O. V. Maltsev, T. G. Kapp, K. Steiger, F. Hoffmann, I. Esposito, W. Weichert, H. Kessler, H.-J. Wester. In-vivo PET Imaging of the Cancer Integrin αvβ6 Using ⁶⁸Ga-Labeled Cyclic RGD Nonapeptides. J. Nucl. Med. 2017, 58, 671–677. DOI:10.2967/jnumed.116.182824

T. G. Kapp, F. Rechenmacher, S. Neubauer, O. V. Maltsev, A. E. Cavalcanti-Adam, R. Zarka, U. Reuning, J. Notni, H.-J. Wester, C. Mas-Moruno, J. Spatz, B. Geiger, H. Kessler*. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. Sci. Rep. 2017, 7, 39805. DOI:10.1038/srep39805

F. Hyafil*, J. Pelisek, I. Laitinen, M. Schottelius, M. Mohring, Y. Döring, E. P. C. van der Vorst, M. Kallmayer, K. Steiger, A. Poschenrieder, J. Notni, J. Fischer, C. Baumgartner, C. Rischpler, S. G. Nekolla, C. Weber, H.-H. Eckstein, H.-J. Wester, M. Schwaiger. Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer ⁶⁸Ga-pentixafor for positron emission tomography. J. Nucl. Med. 2017, 58, 499–506. DOI:10.2967/jnumed.116.179663

★ J. Notni*, H.-J. Wester. A practical guide on synthesis of metal chelates for molecular imaging and therapy by means of click chemistry. Chem. Eur. J. 2016, 22, 11500–11508. DOI:10.1002/chem.201600928

J. Notni*, K. Steiger, F. Hoffmann, D. Reich, M. Schwaiger, H. Kessler, H.-J. Wester. Variation of Specific Activities of Ga-68-Aquibeprin and Ga-68-Avebetrin Enables Selective PET-Imaging of Different Expression Levels of Integrins α₅β₁ and α_vβ₃. J. Nucl. Med. 2016, 57, 1618–1624. DOI:10.2967/jnumed.116.173948

J. Notni*, K. Steiger, F. Hoffmann, D. Reich, T. G. Kapp, F. Rechenmacher, S. Neubauer, H. Kessler, H.-J. Wester. Complementary, Selective PET-Imaging of Integrin Subtypes α₅β₁ and α_vβ₃ Using Ga-68-Aquibeprin and Ga-68-Avebetrin. J. Nucl. Med. 2016, 57, 460–466. DOI:

C. D’Alessandria*, K. Pohle, F. Rechenmacher, S. Neubauer, J. Notni, H.-J. Wester, M. Schwaiger, H. Kessler, A. J. Beer. In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labeled α5β1-selective peptidomimetic FR366. Eur. J. Nucl. Med. Mol Imaging 2016, 43, 953–963. DOI:10.1007/s00259-015-3218-z

★ Z. Baranyai, D. Reich, A. Vágner, M. Weineisen, I. Tóth, H.-J. Wester, J. Notni*. A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform. Dalton Trans. 2015, 44, 11137–11146. DOI:10.1039/c5dt00576k

G. Máté, J. Šimeček, M. Pniok, I. Kertész, J. Notni, H.-J. Wester, L. Galuska, P. Hermann*. The Influence of the Combination of Carboxylate and Phosphinate Pendant Arms in 1,4,7-Triazacyclononane-based Chelators on their ⁶⁸Ga Labelling Properties. Molecules 2015, 20, 13112–13126. DOI:10.3390/molecules200713112

S. Poty, P. Désogère, J. Šimeček, C. Bernhard, V. Goncalves, C. Goze, F. Boschetti, J. Notni, H.-J. Wester, F. Denat*. MA-NOTMP: A Triazacyclononane Trimethylphosphinate Based Bifunctional Chelator for Gallium Radiolabelling of Biomolecules. ChemMedChem 2015, 10, 1475–1479. DOI:10.1002/cmdc.201500198

★ J. Notni*, J. Šimeček, H.-J. Wester. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications. ChemMedChem 2014, 9, 1107-1115. DOI:10.1002/cmdc.201400055

J. Šimeček, O. Zemek, P. Hermann, J. Notni*, H.-J. Wester. The Tailored Gallium(III) Chelator NOPO: Synthesis, Characterization, Bioconjugation, and Application in Preclinical PET Imaging. Mol. Pharmaceutics 2014, 11, 3893–3903. DOI:10.1021/mp400642s

J. Šimeček, J. Notni*, T. G. Kapp, H. Kessler, H.-J. Wester. Benefits of NOPO as chelator in Gallium-68 peptides, exemplified by preclinical characterization of ⁶⁸Ga-NOPO-c(RGDfK). Mol. Pharmaceutics 2014, 11, 1687–1695. DOI:10.1021/mp5000746

J. Notni*, P. Hermann, I. Dregely, H.-J. Wester. Convenient Synthesis of Gallium-68 Labeled Gadolinium(III) complexes: Towards Bimodal Responsive Probes for Functional Imaging with PET/MRI. Chem. Eur. J. 2013, 19, 12602–12606. DOI:10.1002/chem.201302751

★ J. Šimeček, P. Hermann^*, J. Havlíčková, E. Herdtweck, T. G. Kapp, N. Engelbogen, H. Kessler, H.-J. Wester,J. Notni*. A cyclen-based tetraphosphinate chelator for preparation of radiolabeled tetrameric bioconjugates. Chem. Eur. J. 2013, 19, 7748–7757. DOI:10.1002/chem.201300338

I. Laitinen*, J. Notni, K. Pohle, M. Rudelius, E. Farrell, S. G. Nekolla, G. Henriksen, S. Neubauer, H. Kessler, H.-J. Wester, M. Schwaiger. Comparison of cyclic RGD peptides for α_vβ₃ integrin detection in a rat model of myocardial infarction. EJNMMI Res. 2013, 3, 38. DOI:10.1186/2191-219X-3-38

★ J. Šimeček, P. Hermann, H.-J. Wester, J. Notni*. How is ⁶⁸Ga-labelling of macrocyclic chelators influenced by metal ion contaminants in ⁶⁸Ge/⁶⁸Ga generator eluates? ChemMedChem 2013, 8, 95–103. DOI:10.1002/cmdc.201200471

J. Notni*, K. Pohle, H.-J. Wester. Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃. Nucl. Med. Biol. 2013, 40, 33–41. DOI:10.1016/j.nucmedbio.2012.08.006

J. Šimeček, H.-J. Wester, J. Notni*. Copper-64 labelling of triazacyclononane-triphosphinate chelators. Dalton Trans. 2012, 41, 13803–13806. DOI:10.1039/c2dt31880f

★ J. Notni*, K. Pohle, H.-J. Wester. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res. 2012, 2, 28. DOI:10.1186/2191-219X-2-28

J. Šimeček, O. Zemek, P. Hermann, H.-J. Wester, J. Notni*. A monoreactive bifunctional triazacyclononane-phosphinate chelator with high selectivity for Gallium-68. ChemMedChem 2012, 7, 1375–1378. DOI:10.1002/cmdc.201200261

J. Notni*, J. Plutnar, H.-J. Wester. Bone Seeking TRAP Conjugates: Surprising Observations and Implications on Development of Gallium-68-labeled Bisphosphonates. EJNMMI Res. 2012, 2, 13. DOI:10.1186/2191-219X-2-13

K. Pohle*, J. Notni, J. Bussemer, H. Kessler, M. Schwaiger, A. J. Beer. ⁶⁸Ga-NODAGA-RGD is a suitable substitute for ¹⁸F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl. Med. Biol. 2012, 39, 777–784. DOI:10.1016/j.nucmedbio.2012.02.006

★ J. Šimeček, M. Schulz, J. Notni, J. Plutnar, V. Kubíček, J. Havlíčková, P. Hermann*. Complexation of Metal Ions with TRAP (1,4,7-Triazacyclononane-Phosphinic Acid) Ligands and 1,4,7-Triazacyclononane-1,4,7-triacetic Acid: Phosphinate-Containing Ligands as Unique Chelators for Trivalent Gallium. Inorg. Chem. 2012, 51, 577–590. DOI:10.1021/ic202103v

★ J. Notni*, J. Šimeček, P. Hermann, H.-J. Wester. TRAP, a Powerful and Versatile Framework for Gallium-68 Radiopharmaceuticals. Chem. Eur. J. 2011, 17, 14718–14722. DOI:10.1002/chem.201103503

A. Al-Ibraheem, R. A. Bundschuh*, J. Notni, A. Buck, A. Winter, H.-J. Wester, M. Schwaiger, K. Scheidhauer. Focal uptake of ⁶⁸Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 2005–2013. DOI:10.1007/s00259-011-1875-0

★ J. Notni*, P. Hermann*, J. Havlíčková, J. Kotek, V. Kubíček, J. Plutnar, N. Loktionova, P. J. Riss, F. Rösch, I. Lukeš. A triazacyclononane-based bifunctional phosphinate ligand for the preparation of multimeric ⁶⁸Ga tracers for positron emission tomography. Chem. Eur. J. 2010, 16, 7174–7185. DOI:10.1002/chem.200903281

J. Notni*, K. Pohle, J. A. Peters, H. Görls, C. Platas-Iglesias. Structural Study of Ga(III), In(III), and Fe(III) Complexes of Triaza-Macrocycle Based Ligands with N₃S₃ Donor Set. Inorg. Chem. 2009, 48, 3257–3267. DOI:10.1021/ic900119a

J. Notni, S. Schenk, H. Görls, H. Breitzke, E. Anders*. Formation of a Unique Zinc Carbamate by CO₂ Fixation: Implications for the Reactivity of Tetra-Azamacrocycle Ligated Zn(II) Complexes. Inorg. Chem. 2008, 47, 1382–1390. DOI:10.1021/ic701899u

J. Notni, S. Schenk, G. Protoschill-Krebs, J. Kesselmeier, E. Anders*. The Missing Link in COS Metabolism: A Model Study on the Reactivation of Carbonic Anhydrase from its Hydrosulfide Analogue. ChemBioChem 2007, 8, 530–536. DOI:10.1002/cbic.200600436

J. Notni, W. Günther, E. Anders*. Zinc Thiolate Complexes [ZnL_n(SR)]⁺ with Azamacrocyclic Ligands, Part III: The Influence of the Ligand Ln on the Reactivity of the Zinc-bound Thiolate. Eur. J. Inorg. Chem. 2007, 985–993. DOI:10.1002/ejic.200600962

J. Notni, S. Schenk, A. Roth, W. Plass, H. Görls, U. Uhlemann, A. Walter, M. Schmitt, J. Popp, S. Chatzipapadopoulos, T. Emmler, H. Breitzke, J. Leppert, G. Buntkowsky, K. Kempe, E. Anders*. Zinc Thiolate Complexes [ZnL_n(SR)]⁺ with Azamacrocyclic Ligands, Part II: Mechanism of the Reaction with CS₂. Eur. J. Inorg. Chem. 2006, 2783–2791.

J. Notni, H. Görls, E. Anders*. Zinc Thiolate Complexes [ZnL_n(SR)]⁺ with Azamacrocyclic Ligands: Synthesis and Structural Properties. Eur. J. Inorg. Chem. 2006, 1444–1455.